Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial |
| |
Authors: | Connolly Stuart J Dorian Paul Roberts Robin S Gent Michael Bailin Steven Fain Eric S Thorpe Kevin Champagne Jean Talajic Mario Coutu Benoit Gronefeld Gerian C Hohnloser Stefan H;Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients Investigators |
| |
Institution: | Departments of Medicine (Dr Connolly) and Clinical Epidemiology and Biostatistics (Drs Gent and Thorpe, and Mr Roberts), McMaster University, Hamilton, Ontario; Department of Medicine, University of Toronto, Toronto, Ontario (Dr Dorian); Iowa Heart Center, Des Moines (Dr Bailin); St Jude Medical, Cardiac Rhythm Management Division, Sylmar, Calif (Dr Fain); Department of Medicine, University of Laval, Quebec (Dr Champagne); Montreal Heart Institute (Dr Talajic) and Department of Medicine (Dr Coutu), University of Montreal, Montreal, Quebec; and J. W. Goethe University, Frankfurt, Germany (Drs Gronefeld and Hohnloser). |
| |
Abstract: | Context Implantable cardioverter defibrillator (ICD) therapy is effective but is associated with high-voltage shocks that are painful. Objective To determine whether amiodarone plus -blocker or sotalol are better than -blocker alone for prevention of ICD shocks. Design, Setting, and Patients A randomized controlled trial with blinded adjudication of events of 412 patients from 39 outpatient ICD clinical centers located in Canada, Germany, United States, England, Sweden, and Austria, conducted from January 13, 2001, to September 28, 2004. Patients were eligible if they had received an ICD within 21 days for inducible or spontaneously occurring ventricular tachycardia or fibrillation. Intervention Patients were randomized to treatment for 1 year with amiodarone plus -blocker, sotalol alone, or -blocker alone. Main Outcome Measure Primary outcome was ICD shock for any reason. Results Shocks occurred in 41 patients (38.5%) assigned to -blocker alone, 26 (24.3%) assigned to sotalol, and 12 (10.3%) assigned to amiodarone plus -blocker. A reduction in the risk of shock was observed with use of either amiodarone plus -blocker or sotalol vs -blocker alone (hazard ratio HR], 0.44; 95% confidence interval CI], 0.28-0.68; P<.001). Amiodarone plus -blocker significantly reduced the risk of shock compared with -blocker alone (HR, 0.27; 95% CI, 0.14-0.52; P<.001) and sotalol (HR, 0.43; 95% CI, 0.22-0.85; P = .02). There was a trend for sotalol to reduce shocks compared with -blocker alone (HR, 0.61; 95% CI, 0.37-1.01; P = .055). The rates of study drug discontinuation at 1 year were 18.2% for amiodarone, 23.5% for sotalol, and 5.3% for -blocker alone. Adverse pulmonary and thyroid events and symptomatic bradycardia were more common among patients randomized to amiodarone. Conclusions Despite use of advanced ICD technology and treatment with a -blocker, shocks occur commonly in the first year after ICD implant. Amiodarone plus -blocker is effective for preventing these shocks and is more effective than sotalol but has an increased risk of drug-related adverse effects. Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00257959 |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
| 点击此处可从《The Journal of the American Medical Association》浏览原始摘要信息 |
| 点击此处可从《The Journal of the American Medical Association》下载免费的PDF全文 |
|